01—Abstract
Summary
Summary of the 10-K filed February 4, 2011. Cited figures are marked; the original filing is the authoritative source.
Biogen Idec's 2010 10-K report highlights a company focused on neurological disorders with a portfolio driven by AVONEX, TYSABRI, and RITUXAN.
Total revenues grew by 7.7% to $4.7 billiona, primarily fueled by strong performance in AVONEX and TYSABRI, which saw revenue increases of 8.4% and 16.0% respectively. Despite an overall increase in revenue, income from operations saw a slight decrease of 3.6% due to increased restructuring charges, a significant acquired in-process R&D charge, and higher collaboration profit sharing expenses. The company is undergoing a significant strategic shift, announced in late 2010, to focus primarily on neurology and reallocate R&D resources.
This includes terminating or out-licensing oncology and cardiovascular programs and reducing workforce by 13%b. Several business development activities occurred in 2010, including the acquisition of Panima Pharmaceuticals AG and new collaboration terms for ocrelizumab and GA101 with Genentech, alongside a license agreement for dexpramipexole. Investors should note the ongoing safety monitoring and regulatory discussions for TYSABRI related to PML risks.
Looking ahead, Biogen Idec expects continued competition in the Multiple Sclerosis market and is actively managing its product pipeline and operational structure to drive future growth. The company's financial position remains robust with significant cash reserves, and it actively repurchased shares in 2010.
02—Key points
Key Highlights
- Total revenues increased 7.7% to $4.7 billion in 2010, driven by strong sales of AVONEX (up 8.4%) and TYSABRI (up 16.0%).
- Net income attributable to Biogen Idec Inc. increased 3.6% to $1.0 billion.
- Diluted EPS increased 17.6% to $3.94.
- Company announced a strategic restructuring initiative to focus on neurology, reallocate R&D, and reduce workforce by approximately 13%, with expected annual savings of $300 million.
- Significant investment in R&D continues, with $1.25 billion spent in 2010, including a $205 million charge related to the Knopp acquisition.
- TYSABRI sales growth continues despite significant safety warnings related to PML, with ongoing efforts to stratify patient risk.
- RITUXAN revenues saw a slight decrease of 1.6%, largely due to royalty expirations in rest-of-world markets, although U.S. co-promotion profits increased.
- Acquisition of Panima Pharmaceuticals AG completed in December 2010 for up to $395 million in contingent consideration.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2010, Biogen Inc. kept $0.21.
- Revenue$4.72B100.0%
- Cost of revenue−$400.2M8.5%
- Gross profit$4.32B91.5%
- Operating costs−$3.07B65.0%
- Operating income$1.25B26.5%
- Interest, other & tax−$243.6M5.2%
- Net income$1.01B21.3%
Where FY2010 revenue went
$4.72B- R&D: $1.25B, 26% of revenue
- SG&A: $1.03B, 22% of revenue
- Net income: $1.01B, 21% of revenue
- Other operating costs: $787.1M, 17% of revenue
- Cost of revenue: $400.3M, 8.5% of revenue
- Interest, other & tax: $243.6M, 5.2% of revenue
Kept 21% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2010filed February 4, 2011Financial Statements
FY2010 against FY2009
| Line item | FY2010FY2009 | Change |
|---|---|---|
| Revenue | $4.72B$4.38B | +7.7% |
| Cost of Revenue | $400.26M$382.10M | +4.8% |
| Gross Profit | $4.32B$4.00B | +8.0% |
| R&D Expenses | $1.25B$1.28B | −2.7% |
| SG&A Expenses | $1.03B$911.03M | +13.2% |
| Operating Expenses | $3.47B$3.08B | +12.5% |
| Operating Income | $1.25B$1.30B | −3.6% |
| Interest Expense | $36.10M$35.80M | +0.8% |
| Net Income | $1.01B$970.13M | +3.6% |
| EPS (Basic) | $3.98$3.37 | +18.1% |
| EPS (Diluted) | $3.94$3.35 | +17.6% |
| Shares Outstanding (Basic) | 252.31M287.36M | −12.2% |
| Shares Outstanding (Diluted) | 254.87M289.48M | −12.0% |
05—Questions
Frequently Asked Questions
What are Biogen Idec's primary revenue drivers?
Biogen Idec's primary revenue drivers are its marketed products: AVONEX (for multiple sclerosis), TYSABRI (for multiple sclerosis and Crohn's disease), and RITUXAN (for non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia, marketed in collaboration with Genentech). AVONEX and TYSABRI are particularly significant for the company's revenue.
What are the key strategic changes Biogen Idec announced in late 2010?
Biogen Idec announced a strategic shift to focus primarily on neurology, reallocating R&D resources to high-potential programs. This includes discontinuing or out-licensing oncology and cardiovascular programs, reducing its workforce by approximately 13%, and closing facilities to improve efficiency and cost-effectiveness.
What are the major risks highlighted in the filing regarding TYSABRI?
The major risks highlighted for TYSABRI revolve around the serious brain infection progressive multifocal leukoencephalopathy (PML). The risk of PML increases with prior immunosuppressant use and longer treatment duration. The company is actively researching ways to mitigate this risk, including developing a JC virus antibody assay, but ongoing regulatory discussions and potential label changes could impact sales growth.
How does the company manage its international operations and currency risk?
Biogen Idec has global operations and is exposed to foreign currency exchange rate fluctuations. To mitigate this risk, the company uses foreign currency forward contracts to hedge forecasted international revenues and certain balance sheet items. These hedging activities are designed to reduce the volatility of net income and earnings per share.
06—Continue